Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development

被引：0

作者：

Holmlund, JT

Monia, BP

Kwoh, TJ

Dorr, FA

机构：

来源：

CURRENT OPINION IN MOLECULAR THERAPEUTICS | 1999年 / 1卷 / 03期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides for the treatment of cancer. This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals.

引用

页码：372 / 385

页数：14

共 79 条

[1]

Adesina AM, 1998, INT J ONCOL, V12, P759

[2]

ADVANI R, 1999, P AM SOC CLIN ONCOL, V18

[3]

ANDREYEV J, 1997, P ASCO, V16, pA257

[4] THE POTENTIAL OF PROTEIN-KINASE-C AS A TARGET FOR ANTICANCER TREATMENT [J].